Home / Market News / $AQST
fiscal.ai Corporate Catalyst Impact 85/100 ● negative

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Nov 3, 2026, 10:39 PM UTC · Primary ticker $AQST

Aquestive Therapeutics reported a significant revenue decline and wider EBITDA loss for Q3 2026, missing expectations. The company maintained full-year guidance and highlighted a key PDUFA goal date for its Anaphylm product in March 2027, which could be a future catalyst despite the current financial underperformance.

Aquestive Therapeutics reported a substantial 40% year-over-year decline in Q3 2026 revenues, primarily due to fluctuations in Suboxone product orders, and a wider non-GAAP adjusted EBITDA loss. This financial underperformance is a negative short-term indicator for the company. However, the maintenance of full-year guidance and the upcoming PDUFA goal date for Anaphylm in March 2027 present a potential long-term opportunity. Traders should note the immediate negative financial results but also consider the future catalyst of Anaphylm's regulatory decision, which could significantly impact the stock's trajectory.

$AQST negative Revenue decline, wider EBITDA loss
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.